Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 9/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.57 |
| ▸ | HTR3B | O95264 | 5/20 | 0.57 |
| ▸ | HTR3A | P46098 | 5/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.57 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8318106 | 0.98 | ADRB1 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL30892475 | 0.98 | ADRB1 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL28512966 | 0.98 | ADRB1 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5231793 | 0.93 | CHRNB2 (0.50) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL24196401 | 0.83 | MAPT (0.56) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6964650 | 0.83 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1022323 | 0.83 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL20995089 | 0.83 | ADRB1 (0.51) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14995689 | 0.83 | ADRB1 (0.52) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL232655 | 0.83 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| CN-121574100-A | Aminopyrimidine derivative and preparation method and application thereof | 天津市肿瘤医院（天津医科大学肿瘤医院） | 2026-02-27 | — | — | CN | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-RE49698-E1 | Substituted dihydroquinazolines | AIC246 AG & CO. KG (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49698-E1 | Substituted dihydroquinazolines | AIC246 AG & CO. KG (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49698-E1 | Substituted dihydroquinazolines | AIC246 AG & CO. KG (DE) | 2023-10-17 | — | — | US | disclosed |
| CN-111787916-B | Dihydroceramide desaturase inhibitors for treating diseases | 森陶鲁斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-6635647-B2 | Such as (4-(3,4-difluoro-phenyl)-piperazin-1-yl)-((4,4,8)-2-(3-(6-methoxy-pyridin-3 -yl)-2-methyl-propyl)-decahydro-isoquinolin-4-yl)-methanone; schizophrenia, depression, anxiety, bipolar disorders | NOVARTIS AG (CH) | 2003-10-21 | — | — | US | disclosed |
| US-20030120072-A1 | Such as (4-(3,4-Difluoro-phenyl)-piperazin-1-yl)-((4S ,4aS,8aR)-2-((S)-3-(6-methoxy-pyridin-3-yl)-2-methyl-propyl)-decahydro -isoquinolin-4yl)-methanone for treatment of schizophrenia, depression, anxiety and bipolar disorders | NOVARTIS AG (CH) | 2003-06-26 | — | — | US | disclosed |
| WO-2003040125-A1 | PIPERAZINE DERIVATIVES HAVING SST1 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |
| EP-1268466-A1 | DECAHYDRO-ISOQUINOLINES | Novartis AG (CH) | 2003-01-02 | — | — | EP | disclosed |
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | H. LUNDBECK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
| WO-2001070731-A1 | DECAHYDRO-ISOQUINOLINES | NOVARTIS AG (CH) | 2001-09-27 | — | — | WO | disclosed |
| EP-1100794-A1 | COMPOUNDS SPECIFIC FOR THE HUMAN $g(a) 1d? ADRENERGIC RECEPTOR AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000004012-A9 | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000004012-A1 | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | ADRB1 746/4885HTR3E 3135/4885HTR3B 3003/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | ADRB1 2570/4885HTR3E 4178/4885HTR3B 3808/4885 |
| US-20030120072-A1 | Such as (4-(3,4-Difluoro-phenyl)-piperazin-1-yl)-((4S ,4aS,8aR)-2-((S)-3-(6-methoxy-pyridin-3-yl)-2-methyl-propyl)-decahydro -isoquinolin-4yl)-methanone for treatment of schizophrenia, depression, anxiety and bipolar disorders | MC2R, SSTR1, NPY2R | ADRB1 90/4885HTR3E 78/4885HTR3B 11/4885 |
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | ADRA1D, ADRA1A, ADRB1 | ADRB1 3/4885HTR3E 272/4885HTR3B 117/4885 |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | ADRB1 2570/4885HTR3E 4178/4885HTR3B 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.